Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseases
Reuters2026/08/11 12:20- Coya Therapeutics highlighted COYA 302 (low-dose IL-2 with CTLA4-Ig) as its lead neurodegeneration program, with an ALS Phase 2 readout expected in Q1 2027.
- ALSTARS Phase 2 enrollment expected to finish in H2 2026; primary endpoint is ALSFRS-R change from baseline to Week 24 versus placebo.
- Investor-sponsored ALS study (n=4) showed ALSFRS-R stabilization or improvement over 48 weeks; no deaths or serious adverse events reported.
- Dr. Reddy’s deal covers global ALS rights excluding Japan and Latin America; up to about USD 700 million milestones, low-to-mid teens royalties.
- Cash was USD 43.2 million as of June 30, 2026; runway projected into H2 2027; about 23,500,000 shares outstanding.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cantex Mine Development closes second tranche of private placement for $1.01 million proceeds
PVH CEO Stefan Larsson acquires USD 999,999 of common shares
The rebound of the yen may only be temporary, Morgan Stanley bets on arbitrage trades making a comeback, USD/JPY expected to rise to 163.
Morgan Stanley believes that the recent strengthening of the Japanese yen is mainly due to the unwinding of short-term arbitrage trades and market bets on Japanese capital repatriation, rather than any substantial improvement in fundamentals.
Edwards Lifesciences CVP, TAVR Daniel J. Lippis disposes of 619 common shares worth $54,168.69
Crypto prices
More
